Kornimate/medical-research-clean huggingface dataset:
treatment of severe acute respiratory distress syndrome with allogeneic bone marrow-derived mesenchymal stromal cells

Conditions: Acute Respiratory Distress Syndrome, Adult

Summary: this is a multi-center, open-label, non-randomized controlled trial. patients with viral-induced acute respiratory distress syndrome (ards) on extracorporeal membrane oxygenation (ecmo) will be eligible. ten patients will be enrolled and receive allogeneic bone marrow-derived mesenchymal stromal cells (bm-msc). ventilator parameters as well as preoperative clinical characteristics and postoperative clinical outcomes will be registered. routine blood sampling, radiography, and bronchioalveolar lavage will be performed pre- and postoperatively. spirometry, quality of life assessment, and 6 minute walk test will be performed postoperatively. all available data will be collected prospectively. follow-up is 12 months. informed consent will be obtained from relatives to patients meeting the inclusion criteria before the initiation of any study-specific procedures.


Eligibility criteria:
inclusion criteria: * ≥ 18 years of age * viral-induced acute respiratory distress syndrome * ventilator treatment * extracorporeal membrane oxygenation treatment * relatives provide written informed consent exclusion criteria: * none

Keywords: extracorporeal membrane oxygenation
a clinical study to evaluate experimental children's toothpastes in an in-situ caries model

Conditions: Dental Caries

Summary: an in situ model will be used to evaluate and compare enamel remineralization of human enamel specimens after single use of experimental children's toothpastes.


Eligibility criteria:
inclusion criteria: * healthy males and females aged 11 to 14 inclusive who have an unstimulated salivary flow rate of at least 0.2 ml/minute and a stimulated salivary flow rate of at least 0.8 ml/minute (screening visit 1). exclusion criteria: -
ivwatch in prevention of extravasation of vesicants in an oncology setting

Conditions: Oncology; Extravasation

Summary: this study aims to determine the feasibility of using the ivwatch (registered trademark) device to determine if there is an infiltration at the site of a peripheral intravenous (piv) catheter. an infiltration is when the iv fluid leaks out of a vein and into the surrounding tissue. if medication starts leaking outside the vein, it can cause damage to the surrounding tissue. using the ivwatch device may identify leaking fluid before the nurse is able to visually observe the signs or symptoms of the leaking fluid.

primary objective: i. evaluate the feasibility of using the ivwatch device to detect extravasations of peripheral vesicants given in an adult oncology ambulatory population. secondary objective: i. evaluate the clinical outcomes of extravasations that occur with the use of the ivwatch device.

Eligibility criteria:
inclusion criteria: * patients requiring a peripheral iv for infusion of vesicant or vesicant-like agents (chemotherapy, other vesicant medications). * piv must be inserted * participant (or legal representative) must understand the nature of this study and verbally consent with the research study information sheet prior to receiving any study related procedure exclusion criteria: * patients who are not getting a vesicant, irritant or vesicant like fluid infused. * patients who are bruised, scarred, or tattooed in the area of the piv. * patients with skin integrity issues at the site of the piv. * patients who are on "light precautions." * not for use in power injectors. * not for use on mediports, implanted ports, ivad, central lines, picc lines. * patients without a cancer diagnosis.
high-sensitivity troponin t and coronary computed tomography angiography for rapid diagnosis of emergency chest pain

Conditions: Chest Pain; Acute Coronary Syndrome

Summary: * the purpose of this study is to determine the efficacy and safety of an evaluation strategy based on utilization of high sensitivity cardiac troponin t (hsctnt), followed by coronary computed tomography angiography (ccta) in patients with low-intermediate risk chest pain consistent with a possible acute coronary syndrome compared to a standard of care (soc) strategy. * unicentric, randomized, controlled, open label clinical trial that will compare a fast strategy (hsctnt followed by ccta) with a soc strategy (serial ecg and cardiac biomarkers followed by stress/rest imaging study).


Eligibility criteria:
inclusion criteria: * patients with chest pain consistent with possible acute coronary syndrome. * age \> 18 years. * informed consent. exclusion criteria: * previous history of coronary artery disease. * electrocardiogram diagnostic or suggestive of myocardial ischemia. * condition other than coronary artery disease as cause of an imbalance between myocardial oxygen supply and/or demand (eg. anemia, fever, arrhythmias). * chronic kidney disease (gfr \<30 ml/min/1,73 m2). * iodine contrast allergy. * incapability to perform treadmill stress test. * barthel activity of daily living scale index \< 100.

Keywords: chest pain acute coronary syndrome cardiac biomarkers computed coronary tomography angiography emergency department
comparison of conventional versus transverse mini-incision technique for carpal tunnel release

Conditions: Carpal Tunnel Syndrome

Summary: this study aimed at to fill the gaps by comparing the surgical outcomes of the conventional versus transverse mini-incision technique for carpal tunnel syndrome in terms of pain and functional outcomes.

the study findings would be helpful in determining the superiority of one surgical technique over the other for carpal tunnel release so that a quicker return to normal activities and work for those patients could be achieved, causing less pain and scarring. due to frequent healthcare visits, quality of life can also be improved along with a decrease in morbidity.

Eligibility criteria:
inclusion criteria: * any genders * aged between 18 and 70 years * presenting with symptoms of carpal tunnel syndrome for at least 3 months duration, and having a vas score \> 4. exclusion criteria: * patients with wrists with thenar atrophy * those who had previous ctr surgery * local injection for cts * pregnant females * patients suffering from inflammatory arthropathy * polyneuropathy
a comparative study of bat1706 and eu avastin® in patients with advanced non squamous non small cell lung cancer

Conditions: Non-squamous Non-small Cell Lung Cancer

Summary: this is a phase iii, randomized, double blind, multicenter, active comparator, parallel two arm study to compare the efficacy, and to evaluate the safety, and immunogenicity of bat1706 to eu avastin® in patients with previously untreated advanced non-squamous non-small cell lung cancer (nsnsclc) to demonstrate clinical equivalence of bat1706 and eu avastin®.


Eligibility criteria:
inclusion criteria: 1. stage iv nsnsclc or recurrent disease (any stage at initial diagnosis) no longer amenable to curative surgery or local therapy (histologically or cytologically confirmed). 2. no prior systemic therapy for metastatic disease. prior systemic therapy and/or radiotherapy for locally advanced disease is permitted if completed ≥ 6 months prior to randomization. 3. tumors without activating egfr or alk mutation. patients with unknown mutation status or known activating egfr or alk mutation may be included provided the corresponding targeted agent is not available and chemotherapy is the standard of care of the study center. 4. at least one measurable target lesion according to recist 1.1 (appendix 13.4) as confirmed by cir; bone only and brain-only metastases are not allowed. lesions previously treated with radiotherapy are non-target lesion. 5. eastern cooperative oncology group performance status of 0 or 1 and life expectancy \> 3 months based on investigator's judgment. exclusion criteria: 1. diagnosis of small cell carcinoma of the lung, mixed predominant squamous cell carcinoma of the lung, nsclc not otherwise specified. 2. tumor cavitation, tumor invading into large blood vessels or close to large vessels with an increased risk of bleeding, according to investigator's judgment. 3. prior therapy with monoclonal antibodies or small molecule inhibitors against vegf or vegfr, including avastin®. 4. prior systemic therapy for metastatic disease. 5. prior systemic anticancer therapy, or radiotherapy for locally advanced nsnsclc if completed \< 6 months prior to screening. 6. previous malignancy other than nsclc in the last 5 years except for basal cell cancer of the skin or pre invasive cancer of the cervix.
feasibility of estimating the prevalence and management of stage 4 ckd the gard, france

Conditions: Renal Insufficiency, Chronic

Summary: the main objective of this study is to evaluate the feasibility of estimating the prevalence of stage 4 and 5 chronic kidney disease in the gard department of france from data obtained via laboratory databases. to verifiy if the demand for care thus authenticated by laboratory tests is adapted to nephrology care delivery, as recommended by the french high authority of health (has), laboratory data will be compared with those of patients seen by nephrologists in the department.


Eligibility criteria:
inclusion criteria: * chronic kidney disease (stage \>= 4) exclusion criteria: -
the effect of orthopulse™ on the rate of orthodontic tooth movement

Conditions: Malocclusion

Summary: this open label study is designed to evaluate the ability of orthopulse™ to safely and effectively increase the rate of orthodontic tooth movement with fixed appliances.

the primary aim of this study is to determine if daily orthopulse™ use affects the rate of orthodontic tooth movement during alignment with fixed appliances in the mandibular arch. the secondary aim of this study is to determine whether patients treated with orthopulse demonstrate root resorption beyond what is commonly expected during orthodontic treatment. the study also aims to collect confirmatory evidence on the safety of the device.

Eligibility criteria:
inclusion criteria: * eligible and scheduled for full mouth fixed orthodontic treatment * moderate to severe crowding (lii ≥ 3 mm), with no labio-lingually displaced teeth * class i or class ii by 1/2 cusp or less * non-extraction in both arches * age 11- 60 * good oral hygiene * non-smokerinclud exclusion criteria: * pregnant females * patient is currently enrolled in another clinical study * patient decided on invisalign® rather than braces * periodontally involved teeth * use of bisphosphonates (osteoporosis drugs) during the study * patient plans to move over the treatment period * spaces between anterior teeth

Keywords: photobiomodulation orthodontic treatment malocclusion orthopulse™
effect of negative wound pressure on p.s

Conditions: Pressure Sores

Summary: this study will compare the npwt using the npd to the conventional wound dressing and specifically evaluating (i) reduction of wound surface area and depth, (ii) removal of slough and formation of granulation tissue

initial debridement of slough and necrotic tissue was performed in all patients at the time of admission and before their being allocated in a group. it's 3 groups: group (a): conventional dressing : acting by:preventing pus, the findings from the review indicate that decreasing frictional forces transmitted to the patient's skin is achieved by use of a dressing with an outer surface made from a low friction material. the surface of the pu will be cleaned with normal saline and packed with sterilised gauze to cover the wound. dressing changes will be performed once or twice daily depending on the soakage of the dressing. . group (b), negative pressure wound therapy using the electronic-vac : it is believed that the negative pressure assists in removal of interstitial fluid, decreasing oedema, increasing blood flow and reducing tissue bacterial levels, in addition, mechanical deformation of cells is thought to result in protein and matrix molecule synthesis, which increases the rate of cell proliferation and granulation tissue formation, this , in turn , may promote healing . we will place a nonadherent contact layer, such as xeroform between prepared wound bed and foam then applying a contact dressing with sealling using an adhesive drape. the dressing will be connected to the machine through tubing that was connected to the canister. continuous pressure of 200 mm hg will be applied. the dressing will be changed three times a week group (c), negative pressure wound therapy using the romo-vac: the npd will be applied as a bedside procedure with a low-power continuous suction apparatus. we will place nonadherent contact layer, such as xeroform between prepared wound bed and contact dressing with sealling using an adhesive drape. the dressing will be connected to the romo-vac which applying pressure of-60 to -125 mm hg. the romo-vac will be recharged every 5-6 hours and the dressing will be changed three times a week or earlier if there is a soakage/leakage

Eligibility criteria:
inclusion criteria: stages three and four pu as defined by the national pressure ulcer advisory panel (npuap). exclusion criteria: * wound with necrotic tissue unlikely to tolerate debridement. exposed vessels, nerves and or organs. active bleeding. ischemic limb. opening into body cavity
assessment of an investigational frequent replacement silicone hydrogel lens

Conditions: Refractive Ametropia

Summary: the purpose of this clinical trial is to evaluate the safety and performance of an investigational soft contact lens compared to a commercially available soft contact lens when worn in an extended wear modality.

subjects will be expected to attend 9 office visits. the total expected duration of participation for each subject is approximately 12 months.

Eligibility criteria:
inclusion criteria: * able to understand and sign an informed consent form. * willing to attend all scheduled study visits as required per protocol. * willing and able to wear assigned study lenses as required per protocol. * successful wear of spherical daily wear or extended wear frequent replacement soft contact lenses in both eyes during the past 3 months for a minimum of 5 days per week. * manifest cylinder ≤ 0.75 diopter (d) in each eye. * other protocol-specified inclusion criteria may apply. exclusion criteria: * any eye infection, inflammation, or abnormality or disease (including systemic) that contraindicates contact lens wear, as determined by the investigator. * any use of systemic or ocular medications for which contact lens wear could be contraindicated, as determined by the investigator. * history of eye surgery, including refractive surgery. * currently pregnant or breast-feeding. * monovision contact lens wearers. * daily disposable contact lens wearers. * other protocol-specified exclusion criteria may apply.
phase i study in patients with solid tumours

Conditions: Neoplasms

Summary: this study will comprise 2 parts, a dose escalation phase and a dose expansion phase. the 2 phases are part of a single study and described by this single protocol. patients entered into the dose escalation phase will not be entered into the expansion phase. all subjects must be suitable for treatment with either carboplatin and/or paclitaxel.


Eligibility criteria:
inclusion criteria: * life expectancy \> 12 weeks * women defined as post-menopausal * male or female patients with locally advanced or metastatic cancer suitable for treatment with carboplatin and/or paclitaxel exclusion criteria: * inadequate bone marrow reserve * inadequate live function, renal function or low haemoglobin * unresolved toxicity from anti-cancer therapy

Keywords: solid tumors locally advanced or metastatic cancer suitable for treatment with carboplatin and/or paclitaxel
examining the effects of patient information forms, exercise forms and video recordings

Conditions: Hand Injuries; Work-related Injury

Summary: the investigators believe that these information forms, exercise forms and video recordings that provide patient education will contribute to the collaborative approach of the patient and the clinician, the patient's participation in the treatment, the expectation of treatment and results, and their autonomy. the contribution of patient information forms, exercise forms and video recordings, which have become very important in recent years, to different degrees of results will be questioned.

written and visual information can affect outcome measurements in health care. in addition to verbal information and guidance, written and visual information is also frequently recommended. this information increases patients' clinical knowledge, communication, and satisfaction and reduces potential anxiety. forms have been created in various medical fields to inform the patient about medications, applications, and possible risks, and there are many studies on these instruction forms. the effectiveness of patient information forms and exercise forms in physiotherapy and occupational therapy has gained importance in recent years. it is used in areas such as athlete rehabilitation, impingement syndrome, and osteoarthritis. however, only one study was found, especially in the field of hand rehabilitation. the aim of planning this study is to examine the contribution of patient information forms, exercise forms, and video recordings to the clinical and functional results of patients who suffered hand and forearm injuries as a result of a work accident.

Eligibility criteria:
inclusion criteria: * who have a hand or forearm injury as a result of a work-related injury * who has undergone primary surgery/conservative treatment related to the injury * who is literate * who has and can use technological equipment to use visual and audio communication materials (video) exclusion criteria: * who miss the evaluations * who wants to leave the study

Keywords: hand injuries leaflet functional outcome
intrathecaم ketamine, morphine and both for lower abdominal cancer surgery pain

Conditions: Postoperative Pain

Summary: this study investigates the analgesic efficacy and other possible effects of ketamine, morphine, and both together when administered intrathecally for control of postoperative pain following lower abdominal cancer surgeries.


Eligibility criteria:
inclusion criteria: * american society of anesthesia (asa) i-iii patients. * aged 30-50 years. * scheduled for major abdominal cancer surgery. exclusion criteria: * patients with a known allergy to the study drugs. * significant cardiac, respiratory, renal or hepatic disease. * coagulation disorders. * infection at or near the site of intrathecal injection. * drug or alcohol abuse. * bmi \> 30 kg/m2. * psychiatric illnesses that may interfere with perception and assessment of pain.
single vs multi-fraction srs patients on immunotherapy

Conditions: Brain Cancer; Brain Metastases

Summary: this study is meant to compare different surgical approaches to brain cancer.


Eligibility criteria:
inclusion criteria: i. adult patients (≥ 18 years old) with an ecog performance status 0-2 and a life expectancy of 3 months or more. ii. histologically confirmed systemic malignancy with gadolinium contrast-enhanced mri scan demonstrating 1-10 newly diagnosed intraparenchymal brain metastases. iii. well-circumscribed, measureable intraparenchymal brain metastasis(s) with maximum tumor diameter ≤3.0 cm. if multiple metastases are present, the other(s) must not exceed 3.0 cm in maximum diameter. at least one metastasis must be ≥ 0.5 cm in maximum diameter to be considered measurable disease. iv. negative urine or serum pregnancy test done ≤ 21 days prior to ct simulation, for women of child bearing potential only. v. ability to understand and willingness to sign a written informed consent document. vi. must have received immunotherapy (pd-1/pd-l1 and/or ctla-4 inhibitor(s)) within the past 6 months or plan on receiving immunotherapy within the next 1 month. vii. must have a gustave roussy immune score (grim-score) of 0 or 1 (neutrophil-to-lymphocyte ratio \> 6 = 1 point, ldh \> upper limit of normal = 1 point, and albumin \< 3.5 g/dl = 1 point). exclusion criteria: i. diagnosis of germ cell tumor or hematologic malignancy. ii. metastases in the brain stem, midbrain, pons, medulla, or within 7 mm of the optic apparatus (optic nerves, chiasm and optic tracts). iii. diagnosis of leptomeningeal disease. iv. prior srs to an immediately adjacent lesion(s) of interest or to the current lesion(s) of interest. v. prior history of pseudoprogression or radionecrosis from cranial radiotherapy. vi. a neurosurgical resection cavity deemed too large by the radiation oncologist to be treated with a single fraction of stereotactic radiosurgery. vii. contraindications to gadolinium contrast-enhanced mri (eg, non-compatible pacemaker, egfr \<30, gadolinium allergy). viii. a gustave roussy immune score (grim-score) \> 1 (neutrophil-to-lymphocyte ratio \> 6 = 1 point, ldh \> upper limit of normal = 1 point, and albumin \< 3.5 g/dl = 1 point).
study of tumor and blood samples from women with breast cancer

Conditions: Breast Cancer

Summary: rationale: studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. purpose: this research study is looking at tumor and blood samples from women with breast cancer.

objectives: primary * assess relapse locally or remotely using biomarkers collected from primary tumor and blood samples from women with breast cancer during the first 2 years after diagnosis. secondary * evaluate all relapses. * assess survival without relapse. * determine correlation between biomarkers and relapse. outline: primary tumor and blood samples collected during usual care of patients during the first 2 years after diagnosis are analyzed for biomarkers useful in monitoring and diagnosing breast cancer.

Eligibility criteria:
disease characteristics: * diagnosis of infiltrating unilateral breast cancer * no in situ disease (ductal or lobular) * no invasive bilateral synchronous disease * breast cancer at high risk, defined by at least 2 of the following factors: * hormone receptor negative (hr-) * axillary node positive * histopathologic grade iii * high mitotic index (as defined by the curie institute as \> 20 mitoses per 10 high-power fields \[hpf\]) * tumor size ≥ 2 cm * her2-positive (3 + ihc or fish/ichs positive) * triple-negative tumors (hr- and her2-negative) * initial thoracic-abdomino-pelvic and bone scans must be negative * underwent initial surgery patient characteristics: * menopausal status not specified * serum calcium normal (15.3 mg/dl) or normalized within 8 weeks after surgery * no other invasive cancer within the past 5 years * not pregnant or nursing * no psychological, familial, social, or geographical reasons that make monitoring impossible prior concurrent therapy: * see disease characteristics

Keywords: stage ia breast cancer stage ib breast cancer stage ii breast cancer stage iiia breast cancer stage iiib breast cancer stage iiic breast cancer her2-positive breast cancer triple-negative breast cancer estrogen receptor-negative breast cancer